Korro Bio
This role leads analytical development for oligonucleotide drug substance and drug product within the CMC function at Korro Bio. The leader oversees method development, validation, and routine analysis to support an RNA editing therapeutic pipeline from early development through approval. The position manages internal and external analytical activities, contributes to CMC strategy, and ensures compliance with cGMP and regulatory expectations. It is a highly visible role requiring close collaboration across CMC teams and CDMOs in a fast-paced biotech environment.
Korro Bio is a biotechnology company developing precision RNA‑editing therapeutics that edit a single letter on RNA to modulate biological pathways. Their mission is to translate this platform into genetic-medicine solutions for complex, prevalent diseases by advancing a focused therapeutic pipeline. The company emphasizes moving its science toward patient‑facing programs and resources (for example, work relevant to AATD) to deliver targeted, durable treatments.
Korro Bio Stock Gains After Tough 2025 - New Drug Candidate, Analyst Upgrades Boost Outlook
4 days ago
Korro Bio (KRRO) Losses Of US$117.3 Million Test Bullish Narratives On Profitability
4 days ago
JPM26: Korro Bio Looks To Save Itself Despite Unenviable Position
Jan 16, 2026
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Korro Bio.
Korro Bio didn’t post a salary, so this is our estimate from similar listings.
Analysts Offer Insights on Healthcare Companies: Korro Bio (KRRO), Oruka Therapeutics (ORKA) and Gilead Sciences (GILD)
4 days ago
Lead and mentor the Oligonucleotide & Small Molecule CMC Analytical Development team
Denali Therapeutics
Scientist, CMC Analytical
City Therapeutics
Scientific Director, Analytical Development
Neurocrine Biosciences
Senior Scientist, CMC Analytical Lead
Eikon Therapeutics
Principal Scientist to Associate Director, Analytical Development
Structure Therapeutics
Senior Scientist I, Analytical Development - Mass Spectrometry tLNP CMC
AbbVie